Apatinib is a novel small molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2) that competitively binds to the receptor intracellular tyrosine F6 site and highly selectively inhibits VEGFR-2 enzymatic activity, thus blocking the signal transduction pathway after VEGFR binding to VEGFR-2 and inhibiting tumor vascular production [8]. Here, KDR is linked to neoplasm.